Cytosorbents Corporation (CTSO) Financial Statements (2024 and earlier)

Company Profile

Business Address 305 COLLEGE ROAD EAST
PRINCETON, NJ 08540
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13,15219,04822,14522,55230,16443,023
Cash and cash equivalents13,15219,04822,14522,55230,16443,023
Receivables7,0255,5285,6654,9615,1714,577
Inventory, net of allowances, customer advances and progress billings2,0461,7263,4623,5424,9805,445
Inventory2,0461,7263,4623,5424,9805,445
Other undisclosed current assets1,4221,8632,4891,3261,3312,809
Total current assets:23,64428,16533,76032,38141,64755,854
Noncurrent Assets
Operating lease, right-of-use asset12,33412,47012,60412,79412,98213,197
Property, plant and equipment10,50110,69510,74310,71210,2207,849
Restricted cash and investments1,6871,6871,6871,6871,6871,687
Other noncurrent assets4,2784,4454,4374,6954,6704,685
Total noncurrent assets:28,80129,29829,47229,88929,55927,418
TOTAL ASSETS:52,44557,46363,23262,27071,20583,272
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,8362,9952,5062,3482,1294,826
Accounts payable2,8362,9951,6552,3482,1294,826
Accrued liabilities   851   
Deferred revenue   1,517   
Debt      
Other undisclosed current liabilities7,5157,4415,6927,7718,4249,846
Total current liabilities:10,35110,4369,71510,11910,55414,672
Noncurrent Liabilities
Long-term debt and lease obligation5,021 5,00013,00913,09213,172
Long-term debt, excluding current maturities5,021 5,000   
Liabilities, other than long-term debt12,97813,06113,142   
Operating lease, liability12,97813,06113,14213,00913,09213,172
Other undisclosed noncurrent liabilities  5,011 (13,009)(13,092)(13,172)
Total noncurrent liabilities:17,99918,07118,14213,00913,09213,172
Total liabilities:28,35028,50727,85723,12823,64627,844
Equity
Equity, attributable to parent24,09528,95535,37539,14247,56055,428
Common stock444444444444
Additional paid in capital290,199288,514287,000286,129285,005284,048
Accumulated other comprehensive income1,3281,7212,3296,2013,5421,488
Accumulated deficit(267,477)(261,324)(253,998)(253,232)(241,031)(230,152)
Total equity:24,09528,95535,37539,14247,56055,428
TOTAL LIABILITIES AND EQUITY:52,44557,46363,23262,27071,20583,272

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues9,4219,4499,3908,1118,4968,691
Cost of revenue
(Cost of Goods and Services Sold)
(3,402)(3,994)(3,633)(4,494)(3,551)(2,278)
Gross profit:6,0195,4555,7573,6174,9456,414
Operating expenses(12,578)(13,347)(12,113)(12,635)(13,302)(14,205)
Operating loss:(6,559)(7,892)(6,356)(9,017)(8,357)(7,791)
Nonoperating income (expense)4065664,498(3,183)(2,522)(1,175)
Gain (loss), foreign currency transaction, before tax4156614,518(3,230)(2,523)(1,213)
Loss from continuing operations before income taxes:(6,153)(7,326)(1,859)(12,201)(10,879)(8,966)
Other undisclosed income from continuing operations   1,093   
Loss from continuing operations:(6,153)(7,326)(766)(12,201)(10,879)(8,966)
Loss before gain (loss) on sale of properties:(12,201)(10,879)(8,966)
Net loss available to common stockholders, diluted:(6,153)(7,326)(766)(12,201)(10,879)(8,966)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(6,153)(7,326)(766)(12,201)(10,879)(8,966)
Comprehensive loss:(6,153)(7,326)(766)(12,201)(10,879)(8,966)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(393)(608)(3,871)2,6592,053963
Comprehensive loss, net of tax, attributable to parent:(6,546)(7,934)(4,637)(9,542)(8,826)(8,003)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: